Halsos A M, Salo O P, Lassus A, Tjøtta E A, Hovi T, Gabrielsen B O, Fiddian A P
Acta Derm Venereol. 1985;65(1):59-63.
A randomised, double-blind, placebo-controlled, crossover study was conducted in 31 male patients with a history of frequently recurrent genital herpes who received consecutively 200 mg acyclovir and matching placebo by mouth four times a day for 12 weeks each. During acyclovir therapy recurrences were completely prevented in 24 (77%) and were reduced in both frequency and duration in the remainder compared with those occurring during treatment with placebo. The incidence and nature of adverse events reported during each treatment period was virtually identical. No long-term effects on recurrence rates were discernible but chronic suppressive therapy can be considered to offer the means of controlling the severe forms of disease experienced by some patients.
对31名有频繁复发性生殖器疱疹病史的男性患者进行了一项随机、双盲、安慰剂对照的交叉研究。他们连续12周每天口服4次200毫克阿昔洛韦和匹配的安慰剂。在阿昔洛韦治疗期间，24名患者（77%）的复发完全得到预防，其余患者的复发频率和持续时间与服用安慰剂治疗期间相比均有所降低。每个治疗期间报告的不良事件的发生率和性质几乎相同。未发现对复发率有长期影响，但可认为慢性抑制疗法为控制一些患者所经历的严重疾病形式提供了手段。
